Four hot words sum up the heavy policy of Chinese medicine industry in 2017

[market analysis of chinapharma.com] in recent years, there have been frequent policy dividends of traditional Chinese medicine, involving all links of the industry chain of traditional Chinese medicine, including the planning and policies of upstream medicine planting and protection, the policies and opinions of midstream medicine circulation and trade, and the planning of vigorous development of traditional Chinese medicine at the end So what policies will have a greater impact on the development of traditional Chinese medicine industry in 2017? What adjustments and plans have enterprises made around these policies? This paper analyzes it Key words 1 - reform policy "notice on comprehensively pushing forward the comprehensive reform of public hospitals" requires that before September 30, all public hospitals shall cancel drug mark up, except for Chinese herbal pieces Enterprise practice (1) layout of upstream Chinese herbal medicine Kangmei pharmaceutical, shaohuatang and other Chinese herbal medicine enterprises all have Chinese herbal medicine bases to produce the main raw materials needed for Chinese herbal pieces On the one hand, it can reduce the purchase and circulation costs of traditional Chinese medicine and reduce the operating costs of enterprises; on the other hand, it can avoid the risks brought by frequent and substantial changes in the prices of traditional Chinese medicine in the market and maintain a stable profit level (2) add code to arrange the action of Chinese herbal pieces The listed enterprises of Chinese herbal medicine mainly expand the production capacity of factories, build hospitals, medical centers and other medical institutions to expand the sales chain at the lower end, and purchase the upstream production base of Chinese herbal medicine to increase the size of Chinese herbal medicine Typical representative: Cr 39: increase the promotion of primary medical terminal business, use the medical promotion foundation of grade hospitals to extend to county-level hospitals and primary medical institutions, increase the coverage of primary market, and focus on the development of county-level hospitals At the same time, we should actively adjust the product structure of prescription drugs, return to the core concept of traditional Chinese medicine, give full play to the advantages of traditional Chinese medicine, focus on the cultivation of oral medication, so as to promote the value of traditional Chinese medicine in health care, prevention and rehabilitation And increase R & D investment, through clinical and economic research to obtain evidence-based evidence, in order to better meet the needs of diagnosis and treatment Kangmei pharmaceutical industry: the upstream, middle and downstream industries that have basically run through the industrial chain of traditional Chinese medicine, and the production layout has basically covered the whole country In October, Guangdong Hengxiang Pharmaceutical Co., Ltd., which is mainly engaged in Chinese herbal pieces, was purchased to further consolidate its leading position in Chinese herbal pieces In December, the total investment in Guizhou Province is about 5 billion yuan, which will fully participate in the reform and development of Guizhou Province's big health medicine industry, leading in poverty alleviation of traditional Chinese medicine industry, intensive manufacturing of traditional Chinese medicine (Miao medicine), construction and management of medical facilities, big data of medical health, smart pharmacy, modern medicine logistics extension service, innovation and R & D center of traditional Chinese medicine (Miao medicine), comprehensive health care project, etc Regional cooperation Hengkang medical: the financial report shows that in the first half of the year, the revenue of Hengkang medical herbal pieces business was 294 million yuan, accounting for 26.59% of the total revenue Among them, the business of herbal pieces is mainly carried out by hengkangyuan pharmaceutical This year, hengkangyuan increased the investment in Chinese herbal pieces, increased the scale of Chinese herbal pieces of the company, combined with its hospital medical service business line, Chinese Herbal Pieces business gradually entered the subordinate hospitals, achieving a substantial growth Chinese traditional medicine: the leader of traditional Chinese medicine formula granules, continues to accelerate the acquisition of Chinese Herbal Pieces enterprises, accelerate the building of the whole industry chain, and expand the coverage of the value industry chain   Dongsheng Group: at present, it has a classic Chinese medicine industry platform with guangyuyuan as the core and a modern Chinese medicine industry platform with Yunnan Baiyao as the core In the future, Dongsheng Group will continue to focus on the core business of Chinese medicine industry Based on the existing industrial layout, it will further increase the fields of upstream raw material medicine planting, selection, technological innovation and downstream logistics The input of value-added industrial chains such as sales and health services will strive to open up the upstream and downstream industrial chains of traditional Chinese medicine industry and realize the closed-loop service Key word 2 - laws and regulations and policies: the Chinese medicine law was issued in July, which is the first law in the field of Chinese medicine Among them, the protection of traditional Chinese medicine secret recipe will promote the development of traditional Chinese medicine products In October, the opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical and medical devices was released, which clearly proposed that the inheritance and innovation of traditional Chinese medicine should be supported, and the review and approval of classic famous traditional Chinese medicine should be in accordance with the simplified standards; articles 11 and 25 clearly defined that the review and approval of pharmaceutical injections should be strictly enforced and the re evaluation of pharmaceutical injections should be carried out In the same month, the regulations on simplified registration and approval management of traditional Chinese medicine and the requirements for application materials (Draft for comments) were issued, which made it clear that only pharmaceutical and non clinical safety research materials, drug efficacy research and clinical trial data are not required to be reported However, the release of the standard for the production and quality management of traditional Chinese medicine (Revised Version) puts forward requirements for the production and quality management of traditional Chinese medicine, which is applicable to the whole process of planting, breeding or wild tending of traditional Chinese medicine in the production enterprises of traditional Chinese medicine Kangmei pharmaceutical industry: give full play to the company's advantages in the construction and layout of the whole industrial chain of traditional Chinese medicine, carry out business cooperation in combination with Huada gene's practice of scientific research and transformation in medicine, speed up research and construction in the fields of product development of traditional Chinese medicine, gene detection of traditional Chinese medicine, efficacy evaluation of traditional Chinese medicine, and help the development of traditional Chinese medicine industry Good doctor Pharmaceutical Industry: with innovation driven development strategy, a large number of scientific research efforts have been invested in building a brand of traditional Chinese medicine A series of scientific research has been carried out around Kangfuxin Liquid and Periplaneta americana, and fruitful scientific research results have been achieved At the same time, we should vigorously invest in biomedical innovation, not only at the product end, but also at the service end of "integration of medical care and health care" Yunnan Baiyao: it extends from the traditional pharmaceutical field to the big health field, and is committed to building a big health industry platform, mining and cultivating a large variety group of pharmaceutical business department, and actively exploring the development opportunities of personal care market to create new growth points CR 39: adjust the product structure and gradually extend to both ends of health care and rehabilitation Focus on building large products of traditional Chinese medicine, focus on cultivating oral products such as Xuesaitong Soft Capsule and Cinobufacin tablet At the beginning of this year, Xuesaitong Soft Capsule entered the new version of the national medical insurance catalog, opening up space for the future growth of cardiovascular and cerebrovascular oral product line The company's "new mode application of intelligent manufacturing of traditional Chinese medicine formula granules" project was approved as "integrated standardization and new mode application of intelligent manufacturing of MIIT", which provides a good opportunity for the company to further realize intelligent manufacturing Ma Yinglong pharmaceutical industry: adhere to the core positioning of the anorectal and lower digestive tract fields, according to the development idea of "target customer unification and service function diversification", extend the industrial chain to the anorectal diagnosis and treatment industry, vigorously develop internet medical treatment, and actively seek development opportunities around the large health field, forming the whole industrial chain of drug management, diagnosis and treatment technology, and medical service Key word 3 - internationalization policy One belt, one road one belt, one road, was released in January It was clear that by 2020, the new pattern of "one belt and one way" cooperation in Chinese medicine basically came into being, and 30 Chinese medicine overseas centers were co constructed with the countries along the route 20 international standards for Chinese medicine were promulgated, 100 kinds of traditional Chinese medicine products were registered, and 50 demonstration bases for the exchange and cooperation of Chinese medicine were established in 2016-2020   In June, the 13th five year plan for scientific and technological innovation of traditional Chinese medicine was issued, which clearly stated that: improve the international standards of traditional Chinese medicine, form no less than 50 Pharmacopoeia standards and 100 industry standards, realize the registration of 20-30 varieties of traditional Chinese medicine in EMA or EU Member States as traditional drugs, complete the registration of 5-10 varieties of traditional Chinese medicine in developed countries such as Europe and America, and establish a batch of One belt, one road, is to strengthen cooperation between the Chinese medicine research center and the joint laboratory In November, the key task division of the 13th five year plan for healthy aging was released, which emphasized the concept of "developing traditional Chinese medicine for the aged" and "traditional Chinese medicine for the aged" became a highlight Ping An, China: in September, it invested 1.6 billion yuan to acquire 10% of shares in Jincun, a leading Japanese pharmaceutical company After the deal, Ping An will become a major shareholder in Jincun Jincun Co., Ltd is a large pharmaceutical company of Chinese medicine in the world, which produces more than 100 kinds of Chinese medicine and has a high market share in the field of Chinese medicine for medical use In the future, the two sides will set up joint ventures in China to jointly improve the research and development of traditional Chinese medicine and pharmaceutical technology Kangmei pharmaceutical: in 2017, it continued to promote the construction of its subsidiaries, Hong Kong Research Institute and Canadian Research Institute, completed the construction of national Chinese medicine standard project, and was approved to build the research and development and industrialization application platform of Chinese medicine processing auxiliary materials Beijing Tongrentang: at the beginning of December, the first Chinese medicine store of Beijing Tongrentang in Switzerland officially opened This Chinese medicine enterprise has opened more than 130 stores in 26 countries and regions around the world   Xiangxue pharmaceutical: in August, Xiangxue Cambridge International Research Center of traditional Chinese medicine, a wholly-owned subsidiary of Xiangxue pharmaceutical, received a notice from the British drug and Health Products Administration (MHRA) The application for the registration of Banlangen products used to alleviate cold and flu submitted by Xiangxue Cambridge to MHRA was reviewed and approved, becoming the first batch of Chinese pharmaceutical companies applying for Chinese patent medicines in accordance with the requirements of EU directives, marking the number of Xiangxue pharmaceuticals Chinese traditional medicine officially entered the international market At the same time, the botanical drugs developed jointly by Xiangxue pharmaceutical and the United Kingdom have obtained MHRA drug registration in the United Kingdom; stp705 is the first batch of small nucleic acid drugs in China, and kx02 new brain glioma drugs have been approved by FDA of China and the United States for clinical application; a batch of innovative drug clinical research is being carried out in an all-round way Tianshili: driven by innovation and capital, it forms a "four in one" R & D mode At present, we are actively preparing the application materials for the follow-up of the third phase FDA test of Compound Danshen dropping pills At the same time, there are 7 international drug projects under research, 6 applications for FDA (including 4 traditional Chinese medicine and 2 chemical drugs), and another application for EU project Jianya biology: in December, it obtained the B round investment of USD 50 million invested by the wholly-owned subsidiary of Tianshili This round of financing will support the international industrialization development of insulin analogues of gemasia and promote the construction of insulin eco industrial park in the 21st century Keywords four Internet plus policy In January, the State Council issued the notice of "canceling the examination and approval (B and C certificates) of Internet drug trading service enterprises (except for the third-party platform)" The document pointed out that using the Internet information platform to break through the bottleneck of traditional Chinese medicine marketization will completely eliminate the disadvantages of traditional Chinese medicine trade information opacity, high cost and low efficiency, and change the order of Chinese medicine circulation In December, the State Administration of traditional Chinese Medicine issued the guidance on promoting the integrated development of traditional Chinese medicine health services and the Internet The opinion points out that by 2020, the integration and development of TCM health services and the Internet will reach a new level, the online and offline integration will be closer, the industrial chain will be gradually formed, and everyone will basically enjoy TCM services At present, there are three main directions for traditional Chinese medicine enterprises to lay out the Internet: to build their own, to settle in a third-party platform, to lay out o2o, to establish an online pharmacy or purchase platform for individual consumers of traditional Chinese medicine; to build a closed-loop diagnosis and treatment service of traditional Chinese Medicine through the Internet platform; and to build a B2B e-commerce platform for traditional Chinese medicine used for inter enterprise drug transactions,